- ►ucsf.edu [PDF] GA Francis, E Fayard, F Picard, J Auwerx - Annual review of physiology, 2003 - Annual Reviews ▪ Abstract The metabolic nuclear receptors act as metabolic and toxicological
sensors, enabling the organism to quickly adapt to environmental changes by
inducing the appropriate metabolic genes and pathways. Ligands for these ... Cited by 257 - Related articles - BL Direct - All 7 versions
- ►mapleleafmedical.com [PDF] A Carr, C Workman, D Carey, G Rogers, A … - The Lancet, 2004 - Elsevier Limb fat increased by 0·14 kg in the rosiglitazone group and 0·18 kg in the
placebo group (mean difference –0·04 kg [95%CI –0·29 to 0·21]; p=0·74 by
t test), with three participants (one on rosiglitazone and two controls), ... Cited by 235 - Related articles - All 8 versions
K Kotarsky, NE Nilsson, E Flodgren, C Owman … - Biochemical and Biophysical Research …, 2003 - Elsevier Fatty acids, which are essential nutritional components, are also involved in
cardiovascular and metabolic diseases. Here we report a human cell surface
receptor that we name free fatty acid receptor (FFAR), because it is ... Cited by 109 - Related articles - BL Direct - All 4 versions
JK Kim, JJ Fillmore, O Gavrilova, L Chao, T … - Diabetes, 2003 - Am Diabetes Assoc To determine the role of adipocytes and the tissue-specific nature in the
insulin sensitizing action of rosiglitazone, we examined the effects of 3 weeks
of rosiglitazone treatment on insulin signaling and action during ... Cited by 60 - Related articles - BL Direct - All 5 versions
CJ Bailey - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 50 - Related articles - BL Direct - All 5 versions
- ►endojournals.org K Starkey, A Heufelder, G Baker, W Joba, M … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc A male type-2 diabetic, treated with the peroxisome proliferator-activated
receptor (PPAR) agonist, Pioglitazone, experienced exacerbation of his thyroid
eye disease (TED), which had been stable and inactive for more then 2 yr. ... Cited by 48 - Related articles - BL Direct - All 5 versions
M Gurnell - Clinical Endocrinology, 2003 - interscience.wiley.com Diabetes, obesity, atherosclerosis and cancer are the principal contributors to
morbidity and mortality in Western society. Emerging evidence indicates that a
nuclear receptor, the peroxisome proliferator-activated receptor γ ... Cited by 44 - Related articles - BL Direct - All 9 versions
WP Cawthorn, JK Sethi - FEBS letters, 2008 - Elsevier Dyslipidemia and insulin resistance are commonly associated with catabolic or
lipodystrophic conditions (such as cancer and sepsis) and with pathological
states of nutritional overload (such as obesity-related type 2 diabetes). ... Cited by 40 - Related articles - All 12 versions
- ►physiology.org JG Granneman, P Li, Z Zhu, Y Lu - American Journal of Physiology- Endocrinology And …, 2005 - Am Physiological Soc Selective agonists of 3 -adrenergic receptors (Adrb3) exhibit potent
anti-diabetes properties in rodent models when given chronically, yet the
mechanisms involved are poorly understood. A salient feature of chronic ... Cited by 39 - Related articles - BL Direct - All 4 versions
